N/A
Completed N=70
Perioperative Multimodal General AnesTHesia Focusing on Specific CNS Targets in Patients Undergoing carDiac surgERies
Postoperative Delirium · Hemodynamic Instability · Postoperative Pain · Neurocognitive Dysfunction
Source: ClinicalTrials.gov NCT05279898 ↗
Enrolled (actual)
70
Serious AEs
0.0%
Results posted
Nov 2025
Primary outcomePrimary: Increase in Plasma IL-6 Levels — 15; 29.5; 80.5; 97.7 pg/mL
Summary
In the PATHFINDER 2 trial, the study investigators will test the intraoperative EEG-guided multimodal general anesthesia (MMGA) management strategy in combination with a postoperative protocolized analgesic approach to:
1. reduce the incidence of perioperative neurocognitive dysfunction in cardiac surgical patients
2. ensure hemodynamic stability and decrease use of vasopressors in the operating rooms
3. reduce pain and opioid consumption postoperatively
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Increase in Plasma IL-6 Levels |
15; 29.5; 80.5; 97.7; 115.7; 164 | — |
| PRIMARY Increase in Plasma Neurofilament Light Levels |
40.9; 28.6; 37.4; 25.8; 56.8; 52.8 | — |
| SECONDARY Opioid Consumption |
132.42; 126.93 | — |
| SECONDARY Pain Scores |
4.33; 4.72 | — |
| SECONDARY Burst Suppression |
4.83; 1.68 | — |
| SECONDARY Postoperative Delirium |
8; 9 | — |
| SECONDARY Cognitive Function |
18.421; 18.174; 18.100; 18.960 | — |
| SECONDARY Hemodynamic Stability - Total Vasopressor Dose |
1109.425; 2358.042 | — |
Eligibility Criteria
Inclusion Criteria
- Age ≥ 60 years
- Undergoing any of the following types of surgery with cardiopulmonary bypass limited to coronary artery bypass surgery (CABG), CABG+valve surgeries and isolated valve surgeries.
Exclusion Criteria
- Preoperative left ventricular ejection fraction (LVEF) 2 drinks per day) or drug abuse Active (in the past year) history of alcohol abuse (≥5 drinks/day for men or ≥4 drinks/day for women) as determined by reviewing medical record and history given by the patient
- Liver dysfunction (liver enzymes > 4 times the baseline, all patients will have a baseline liver function test evaluation), history and examination suggestive of jaundice.
Data sourced from ClinicalTrials.gov (NCT05279898). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.